myriad genetics glp-1 receptor agonist weight management diabetes treatments Agonists and Research to Treat Overeating and Substance Use Disorders HKUMed reveals genetic evidence that

CivicScience offers insights into the impact of cost, side effects & trends in GLP-1 usage.

A 2026 case report describes a 34-year-old man with obesity and alcohol use disorder whose semaglutide treatment for weight loss was associated with a marked drop in drinking over 10 months, with his AUDIT score falling from 27 to 7 and alcohol use dropping from about 15 drinks per week to half a beer per month

Explore the pros and cons of GLP-1 medications for managing type 2 diabetes and weight loss.

start in minutes.

Eli Lilly and Novo Nordisk are closing in on deals with the Trump administration that would exchange deep discounts on their weight loss drugs for coverage under Medicare, per Endpoints News